H.C. Wainwright analyst Ed Arce raised the firm’s price target on Genfit to $9 from $8 and keeps a Buy rating on the shares. The analyst is confident that elafibranor hits the primary endpoint in ELATIVE, and expects the readout to "represent a major stock catalyst."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GNFT: